الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
This study is cross sectional, case-control study including patients with β-thalassemia who regularly attended Hematology- Oncology Clinic, Children`s Hospital, Ain Shams University. In the period from January 2013 to December 2014.Their ages varies from 7 to 18 years old.
This study aim was to investigate the plasma lipid profile and lipoprotein-associated phospholipase A2 in the Egyptian children with β-thalassemia and to clarify the disease associations that may underline the alterations of the enzyme observed in patients with β-thalassemia.
The study included 60 patients with β-thalassemia; 35 patients with β-thalassemia major, and 25 patients with β- thalassemia intermedia.
In addition, 20 age and sex matched healthy subjects were included, serving as control group.
Patients with BMI > 25, or history of diabetes mellitus, hypertension or history of hepatitis C viral infection were excluded from the patients` group.
After informed consent all patients were subjected to full history taking and data collection from patients, care takers and patients’ records including: age, sex, place of residence, age of onset of blood transfusion, transfusion frequency and transfusion index (Cc/Kg/Year packed RBCs), history of splenectomy, history of thrombosis including: deep venous thrombosis, previous stroke or transient ischemic attacks, history of any pulmonary or cardiac complications, other medical diseases e.g. hypertension, diabetes mellitus, drug history including chelation type, compliance & other medications, history of Viral Hepatitis B or C, and family history of thrombosis, stroke or ischemic heart disease.
Thorough clinical examination was performed, with emphasis on: weight, height centiles. Body mass index (BMI; kg/m2) was calculated from height and weight measured, pubertal assessment by tanner staging, splenectomy scar, cardiovascular assessment: HR, Blood pressure, cardiac murmurs, and neurological assessment for neurological deficits.
Laboratory Assay was performed including:
a- CBC including Hb%, Hct value, platelets, WBCs.
b- Mean serum ferritin in the preceding 6 months.
c- Hb electrophoresis, level of Hb F, Hb S and other abnormal Hb.
d- Chemistry analysis involving measurements of serum lipid levels, including Total-Cholesterol, high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) and Low density lipoproteins (LDL).
e- Quantitative determination of human lipoprotein-associated phospholipase A2 concentration in plasma.
The results revealed that the patients with β-thalassemia have abnormal lipid profile:-Patients with β-thalassemia show significantly high plasma levels of lipoprotein associated phospholipase A2, these parameters being significantly higher in β-TM compared with β-TI patients.
The TG level shows significant increase in BTM patients than BTI and control groups (p 0.01).
HDL-cholesterol was lower in the patients with β-Thalassemia than in the control group.
Serum ferritin level it significantly high in patients with β-thalassemia, these parameters being significantly higher in β-TM compared with β-TI patients.
Mean Hemoglobin level in the BTM and BTI groups were significantly lower than the control group (p < 0.01).
Duration of illness shows high significant increase in BTM patients group than BTI patients group. Also there was positive significant correlation between Lp-PLA2 and the duration of illness.
As regard transfusion index there was significant increase with BTM patients group than BTI patients group (p< 0.01) also there was positive significant correlation between Lp-PLA2 and transfusion index.
It was found that there was a significant increase in Lp-PLA2 in patients without splenectomy than splenectomized patients (p < 0.05).